source
- Intellia's in-body CRISPR therapy achieves first Phase 3 successIntellia announced that its experimental in vivo CRISPR gene‑editing therapy has completed a Phase 3 trial with positive results. This is the first instance of a CRISPR‑based treatment delivered d…
- Intellia's single-dose CRISPR therapy slashes hereditary angioedema attacks by 87% in Phase 3 trialIntellia Therapeutics reported that its CRISPR-based gene editing drug lonvo-z achieved a dramatic reduction in swelling attacks for patients with hereditary angioedema (HAE) in a Phase 3 study. T…